Blood-brain barrier models: Rationale for selection.

Animal modeling Brain targeting Cerebral capillaries Drug delivery In vivo-in vitro correlation Nanotechnology

Journal

Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523

Informations de publication

Date de publication:
09 2021
Historique:
received: 10 02 2021
revised: 21 06 2021
accepted: 01 07 2021
pubmed: 12 7 2021
medline: 18 1 2022
entrez: 11 7 2021
Statut: ppublish

Résumé

Brain delivery is a broad research area, the outcomes of which are far hindered by the limited permeability of the blood-brain barrier (BBB). Over the last century, research has been revealing the BBB complexity and the crosstalk between its cellular and molecular components. Pathologically, BBB alterations may precede as well as be concomitant or lead to brain diseases. To simulate the BBB and investigate options for drug delivery, several in vitro, in vivo, ex vivo, in situ and in silico models are used. Hundreds of drug delivery vehicles successfully pass preclinical trials but fail in clinical settings. Inadequate selection of BBB models is believed to remarkably impact the data reliability leading to unsatisfactory results in clinical trials. In this review, we suggest a rationale for BBB model selection with respect to the addressed research question and downstream applications. The essential considerations of an optimal BBB model are discussed.

Identifiants

pubmed: 34246710
pii: S0169-409X(21)00251-9
doi: 10.1016/j.addr.2021.113859
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

113859

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Amira Sayed Hanafy (AS)

Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt.

Dirk Dietrich (D)

Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.

Gert Fricker (G)

Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls University, Heidelberg, Germany.

Alf Lamprecht (A)

Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany. Electronic address: alf.lamprecht@uni-bonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH